Skip to main content

Research Repository

Advanced Search

A myristoyl amide derivative of doxycycline potently targets cancer stem cells (CSCs) and prevents metastasis, without retaining antibiotic activity

Ozsvari, B; Magalhaes, LG; Latimer, J; Kangasmetsa, J; Sotgia, F; Lisanti, MP

Authors

B Ozsvari

LG Magalhaes

J Kangasmetsa



Abstract

Here, we describe the chemical synthesis and biological activity of a new Doxycycline derivative, designed specifically to more effectively target cancer stem cells (CSCs). In this analogue, a myristic acid (14 carbon) moiety is covalently attached to the free amino group of 9-amino-Doxycycline. First, we determined the IC50 of Doxy-Myr using the 3D-mammosphere assay, to assess its ability to inhibit the anchorage-independent growth of breast CSCs, using MCF7 cells as a model system. Our results indicate that Doxy-Myr is >5-fold more potent than Doxycycline, as it appears to be better retained in cells, within a peri-nuclear membranous compartment. Moreover, Doxy-Myr did not affect the viability of the total MCF7 cancer cell population or normal fibroblasts grown as 2D-monolayers, showing remarkable selectivity for CSCs. Using both gram-negative and gram-positive bacterial strains, we also demonstrated that Doxy-Myr did not show antibiotic activity, against Escherichia coli and Staphylococcus aureus. Interestingly, other complementary Doxycycline amide derivatives, with longer (16 carbon; palmitic acid) or shorter (12 carbon; lauric acid) fatty acid chain lengths, were both less potent than Doxy-Myr for the targeting of CSCs. Finally, using MDA-MB-231 cells, we also demonstrate that Doxy-Myr has no appreciable effect on tumor growth, but potently inhibits tumor cell metastasis in vivo, with little or no toxicity. In summary, by using 9-amino-Doxycycline as a scaffold, here we have developed new chemical entities for their further development as anti-cancer agents. These compounds selectively target CSCs, e.g., Doxy-Myr, while effectively minimizing the risk of driving antibiotic resistance. Taken together, our current studies provide proof-of-principle, that existing FDA-approved drugs can be further modified and optimized, to successfully target the anchorage-independent growth of CSCs and the process of tumor cell metastasis. Based on these findings, we propose that it may be more appropriate to refer to tumor-spheres as metasta-spheres, to better reflect the close relationship between 3D anchorage-independent growth and metastasis.

Citation

Ozsvari, B., Magalhaes, L., Latimer, J., Kangasmetsa, J., Sotgia, F., & Lisanti, M. (2020). A myristoyl amide derivative of doxycycline potently targets cancer stem cells (CSCs) and prevents metastasis, without retaining antibiotic activity. Frontiers in Oncology, 10, 1528. https://doi.org/10.3389/fonc.2020.01528

Journal Article Type Article
Acceptance Date Jul 16, 2020
Online Publication Date Sep 15, 2020
Publication Date Sep 15, 2020
Deposit Date Jul 29, 2020
Publicly Available Date Sep 15, 2020
Journal Frontiers in Oncology
Publisher Frontiers Media
Volume 10
Pages 1528
DOI https://doi.org/10.3389/fonc.2020.01528
Publisher URL https://doi.org/10.3389/fonc.2020.01528
Related Public URLs http://frontiersin.org/Oncology

Files





You might also like



Downloadable Citations